Comparative Pharmacology
Head-to-head clinical analysis: BLEPH 10 versus POLYTRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEPH 10 versus POLYTRIM.
BLEPH-10 vs POLYTRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydrofolate, thereby inhibiting bacterial folic acid synthesis and exerting bacteriostatic activity.
Polymyxin B sulfate binds to the lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, disrupting membrane integrity and causing cell death. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
Instill 1-2 drops into the conjunctival sac every 3-4 hours, initially up to every 2 hours for severe infections.
1 drop in the affected eye(s) every 4 hours for 7-10 days.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life of polymyxin B is 4.5-6 hours; for trimethoprim it is 8-10 hours. In renal impairment, half-life of both components is prolonged.
Renal excretion of unchanged drug accounts for approximately 50-70% of the dose; biliary/fecal excretion is minimal (<10%).
Renal excretion accounts for approximately 40% of the dose as unchanged polymyxin B and 60% as unchanged trimethoprim. Biliary/fecal elimination is minimal (<5% for each component).
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic